FEZAGEPRAS

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H18O2
Molecular Weight	206.2808
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FEZAGEPRAS

Structure Search

SMILES

CCCCCC1=CC=CC(CC(O)=O)=C1

InChI

InChIKey=PEGQOIGYZLJMIB-UHFFFAOYSA-N

InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)

HIDE SMILES / InChI

Molecular Formula	C13H18O2
Molecular Weight	206.2808
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:29:44 UTC 2023` Edited by `admin` on `Sat Dec 16 17:29:44 UTC 2023`
Record UNII	879OVM0Y1S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FEZAGEPRAS

Official Name

English

2-(3-PENTYLPHENYL)ACETIC ACID

Systematic Name

English

SETOGEPRAM

Common Name

English

PBI-4050

Code

English

3-PENTYLBENZENEACETIC ACID

Systematic Name

English

fezagepras [INN]

Common Name

English

BENZENEACETIC ACID, 3-PENTYL-

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/16/1810

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

Code System Code Type Description

FDA UNII

879OVM0Y1S

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

PUBCHEM

24749700

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

SMS_ID

100000177187

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

CAS

1002101-19-0

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

DRUG BANK

DB15447

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

NCI_THESAURUS

C171674

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

INN

10332

Created by admin on Sat Dec 16 17:29:45 UTC 2023 , Edited by admin on Sat Dec 16 17:29:45 UTC 2023

PRIMARY

Related Record Type Details


					YV4PNL971B

FREE FATTY ACID RECEPTOR 1

TARGET -> AGONIST

Amount:


					R05571KE07

SETOGEPRAM SODIUM

SALT/SOLVATE -> PARENT

Amount:


					T1ZHZ59KKR

G-PROTEIN COUPLED RECEPTOR 84

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					879OVM0Y1S

ACTIVE MOIETY

Comments:

Originator: ProMetic Life Sciences; Developer: ProMetic Life Sciences, Vanderbilt University; Class: Anti-inflammatory, Antifibrotic, Small molecule; Mechanism of Action: Cell differentiation modulator, Colony stimulating factor stimulant, Cytokine modulator, Erythropoiesis stimulant, Extracellular matrix protein inhibitor, Extracellular matrix protein modulator, Immunomodulator, Inflammation mediator inhibitor, Inflammation mediator modulators; Orphan Drug Status: Yes for Idiopathic pulmonary fibrosis; New Molecular Entity: Yes; Highest Development Phases: Phase II for Idiopathic pulmonary fibrosis, Inborn genetic Disorders, Metabolic syndrome/ Phase I/II for Diabetic nephropathies/ Preclinical for Cystic fibrosis, Renal fibrosis, Scleroderma/; No development reported for Anaemia, Haematological disorders, Neutropenia

Amount: